Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Hepatology Research

Volumn 41, Issue 4, 2011, Pages 296-302

  Morimoto, Manabu ^a   Numata, Kazushi ^a   Kondo, Masaaki ^a   Hidaka, Hisashi ^b   Takada, Juichi ^b   Shibuya, Akitaka ^b   Kobayashi, Satoshi ^c   Ohkawa, Shinichi ^c   Okuse, Chiaki ^d   Morita, Satoshi ^e   Taguri, Masataka ^e   Tanaka, Katsuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse drug reaction; Dosage; Elderly; Hepatocellular carcinoma; Sorafenib; Survival

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGE; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPANESE; LIVER CELL CARCINOMA; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79952823438     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00778.x     Document Type: Article

References (21)

1. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-8.
2. Llovet JM, Di Bisceglie AM, Bruix J etal. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
3. Wilhelm SM, Carter C, Tang L etal. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
7. Yau T, Chan P, Ng KK etal. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
8. Morimoto M, Numata K, Kondo M etal. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group (in Japanese with English abstract). Kanzo 2010; 51: 411-7.
9. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
10. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Tokyo: Kanehara, 2008.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
12. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3: 19.
13. Yoshida T, Hisamoto T, Akiba J etal. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006; 25: 6056-66.
14. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010; 15: 242-55.
15. Liu L, Cao Y, Chen C etal. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
16. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
17. van der Veldt AA, Boven E, Helgason HH etal. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99: 259-65.
18. Ramalingam SS, Dahlberg SE, Langer CJ etal. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26: 60-5.
19. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol 2010; 5: 59-63.
20. Escudier B, Eisen T, Stadler WM etal. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8.
21. Ozenne V, Paradis V, Pernot S etal. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106-10.